Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...

MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases with a market capitalization of $74 million, announced today that the U.S ...

Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based ...

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for ...

Annovis Bio has a 1 year low of $4.21 and a 1 year high of $20.00. Annovis Bio ( NYSE:ANVS – Get Free Report ) last released its quarterly earnings results on Friday, November 8th.

(MENAFN- GlobeNewsWire - Nasdaq) MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug ...

Annovis Bio’s buntanetap receives US patent for treatment and prevention of acute brain or nerve injuries: Malvern, Pennsylvania Thursday, January 16, 2025, 17:00 Hrs [IST] Anno ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...